Barrington Research Reiterates “Outperform” Rating for LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Barrington Research in a research note issued on Tuesday,Benzinga reports. They presently have a $95.00 price objective on the medical instruments supplier’s stock. Barrington Research’s price objective suggests a potential upside of 4.01% from the stock’s current price.

Separately, Cantor Fitzgerald increased their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $97.60.

LeMaitre Vascular Trading Down 1.0%

Shares of LMAT stock traded down $0.95 on Tuesday, hitting $91.34. The company had a trading volume of 24,131 shares, compared to its average volume of 189,578. The firm has a market cap of $2.07 billion, a P/E ratio of 44.44, a P/E/G ratio of 2.37 and a beta of 0.79. The stock’s 50-day moving average is $90.69 and its two-hundred day moving average is $86.05. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The business had revenue of $63.15 million during the quarter, compared to analysts’ expectations of $62.48 million. During the same quarter last year, the firm posted $0.52 earnings per share. The firm’s revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, equities research analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Insider Transactions at LeMaitre Vascular

In other news, Director John A. Roush sold 6,561 shares of the firm’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the transaction, the director owned 2,916 shares of the company’s stock, valued at approximately $274,104. This represents a 46.16% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 120,815 shares of company stock worth $11,280,206. 9.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently bought and sold shares of the company. Geneva Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 6.0% during the second quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock valued at $76,010,000 after buying an additional 51,489 shares during the last quarter. Congress Asset Management Co. lifted its position in LeMaitre Vascular by 4.6% during the second quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock valued at $55,973,000 after purchasing an additional 29,553 shares during the period. First Trust Advisors LP raised its position in shares of LeMaitre Vascular by 52.7% in the second quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock worth $50,829,000 after acquiring an additional 211,280 shares during the period. Geode Capital Management LLC raised its position in shares of LeMaitre Vascular by 3.0% in the second quarter. Geode Capital Management LLC now owns 519,792 shares of the medical instruments supplier’s stock worth $43,174,000 after acquiring an additional 15,036 shares during the period. Finally, Northern Trust Corp raised its position in shares of LeMaitre Vascular by 5.4% in the first quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock worth $28,993,000 after acquiring an additional 17,748 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.